Less than two months after the Food and Drug Administration approved the first-ever drug that uses a Nobel-winning technique to mute disease-causing genes, the pharmaceutical industry is already looking for a piece of the next one.

Within the last month, Eli Lilly, Alexion, and Janssen have all announced licensing and collaboration deals — each potentially worth billions — with companies developing treatments with the technique known as RNAi.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • There is no way in hell Alnylam’s patisiran will sell $1B . It’s in a highly competitive market with a narrow label and IV infusion every 3 weeks.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy